Since the beginning of this year, Dexeus Mujer has adopted the @Trisonim test universally. This is one of the most accurate and reliable non-invasive prenatal screening tests on the market.

The screening programme is carried out around the 12th week of pregnancy and allows for the detection of the most common chromosomal abnormalities, such as trisomy 21, with a detection rate close to 99%, and trisomies 13 and 18, with a detection rate of approximately 98%.

At the patient’s request, the test can also screen for abnormalities in the remaining autosomal chromosomes, as well as in the sex chromosomes.

Since it enables the analysis of copy number variations (CNVs) larger than 5 megabases, this test can detect up to 93 microdeletion and microduplication syndromes, including DiGeorge syndrome, which is the most common genetic disorder after Down syndrome (1 in 2,000 births).

Finally, in addition to all the aforementioned abnormalities and the syndromes associated with microdeletions and microduplications, the @Trisonim test also detects point mutations – up to 6,243 pathogenic variants – associated with over 200 severe dominant monogenic diseases, for which no other prenatal test is currently available.